|
|
174 avenue de France, Paris cedex 13
Paris cedex 13, 75365 France
phone:+33 (0)1 53 77 40 00
fax:82-2-2167-9157
|
|
| Symbol |
SAN |
| Exchange |
NYSE |
| Founded |
0 |
| Employees |
75567 |
|
|
| www.sanofi-aventis.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Research and development company |
|
| Management |
| Jean-Fran�ois Brin, Senior Vice President, Pharmaceutical Customer Solutions; Pierre Chancel, Senior Vice President, Global Diabetes; Olivier Charmeil, Senior Vice President, Pharmaceutical Operations Asia/Pacific and Japan; Belen Garijo, Senior Vice President, Pharmaceutical Operations Europe and Canada (excluding France); Gregory Irace, Senior Vice President, Pharmaceutical Operations United States |
| |
|
|
|
|
|
|
| |
|
|
|
|
| Keywords |
| lantus, taxotere, aprovel, plavix, vaccines business |
|
|
|
|
|
|
| Description |
|
Sanofi-Aventis is a pharmaceutical company with a vision to become a diversified global healthcare leader with a broad platform of offerings. The company has been engaged in vaccines, biologicals, branded generics, and consumer healthcare (OTC) and is aiming to further develop its R&D efforts. The Sanofi-Aventis strategy is built around three priorities to reach its goals and ensure sustainable growth: innovation in research and development, adaption of group structures, external growth opportunities. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members